Xinjiang Bai Hua Cun Pharma Tech (600721.SH) reported a forecasted increase, with an estimated net profit of 36 to 46 million yuan for the year 2024, representing a year-on-year increase of 177.56% to 254.66%.

20/01/2025

Baihua Pharmaceutical (600721.SH) announced that the company is expected to achieve net profit attributable to shareholders of listed companies in 2024...

Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 36 million to 46 million yuan in 2024, an increase of 23.03 million to 33.03 million yuan compared to the same period last year, representing a year-on-year increase of 177.56% to 254.66%. During the reporting period, the company intensified market promotion, enhanced technical capabilities, improved research and development efficiency, shortened project delivery cycles, strengthened cost control, and achieved significant profit growth through increased operating income, reduced project research and development costs, and increased gross profit.

HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.

HK Stock Market Move | Some concept stocks of innovative drugs are rising, and two departments have issued documents to promote the development of innovative drugs. Citi believes that the sector will usher in multiple catalysts in the second half of the year.

A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.

HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.

A-share market opening express | Three major indexes rise and fall differently. Brain-computer interface sector leads in gains.